Consolidated Net Income/Loss: A company's total income or loss before preferred stock dividends.
Nuvation Bio Inc. (NUVB) had Consolidated Net Income/Loss of $-55.79M for the most recently reported fiscal quarter, ending 2025-09-30.
| Income Statement Financials | |
$13.12M |
|
$-55.79M |
|
$3.35M |
|
$9.77M |
|
$69.55M |
|
$-56.43M |
|
$0.64M |
|
$-55.79M |
|
$-55.80M |
|
$-55.79M |
|
$-55.79M |
|
|
Consolidated Net Income/Loss |
$-55.79M |
$-55.80M |
|
$-56.43M |
|
$-55.58M |
|
342.39M |
|
342.39M |
|
$-0.16 |
|
$-0.16 |
|
| Balance Sheet Financials | |
$577.53M |
|
$0.56M |
|
$24.03M |
|
$601.56M |
|
$68.13M |
|
$47.09M |
|
$207.55M |
|
$275.68M |
|
$325.88M |
|
$314.20M |
|
$325.88M |
|
342.76M |
|
| Cash Flow Statement Financials | |
$-143.69M |
|
$12.44M |
|
$194.47M |
|
$35.72M |
|
$98.90M |
|
$63.17M |
|
$27.91M |
|
-- |
|
-- |
|
| Fundamental Metrics & Ratios | |
8.48 |
|
-- |
|
-- |
|
0.13 |
|
0.16 |
|
74.47% |
|
-430.14% |
|
-430.14% |
|
-- |
|
-425.24% |
|
-425.24% |
|
$-143.96M |
|
-- |
|
-- |
|
-- |
|
0.02 |
|
0.59 |
|
0.95 |
|
95.01 |
|
-17.12% |
|
-17.76% |
|
-9.27% |
|
-14.96% |
|
$0.95 |
|
$-0.42 |
|
$-0.42 |
|